{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-053897","form_type":"8-K","ticker":"CTKB","cik":"0001831915","company_name":"Cytek Biosciences, Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.916708+00:00","generated_at":"2026-06-18T22:39:36.535276+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cytek Q4 revenue $48.3M (+24% YoY); guides FY2023 $225-235M (+37-43%)","bullets":["Full-year 2022 revenue $164.0M, up 28% YoY (34% constant currency); net income $2.5M.","Q4 net income $3.7M vs loss $1.2M in Q4 2021; adjusted EBITDA $6.6M.","2023 revenue guidance $225-235M, including ~$20M from Luminex acquisition closed Feb 28.","Acquired Luminex's Flow Cytometry and Imaging business; partnership with Bio-Rad.","Cash and short-term investments $341.1M; 560 instrument placements in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-053897","json":"https://secwatch.observer/filing/0001193125-23-053897.json","markdown":"https://secwatch.observer/filing/0001193125-23-053897.md","text":"https://secwatch.observer/filing/0001193125-23-053897.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831915/000119312523053897/0001193125-23-053897-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831915/000119312523053897/d462230d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T22:39:36.535276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d9be189c93831ee4064f0d5ee1e5b0de6157b40","claim":"Cytek Biosciences, Inc. reported full year 2023 results: revenue $225 million to $235 million. Guidance initiated.","evidence_excerpt":"Cytek Biosciences expects full year 2023 revenue in the range of $225 million to $235 million, representing growth of 37% to 43% over full year 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831915/000119312523053897/0001193125-23-053897-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$225 million to $235 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"62b81caa5457308c03b5185338eaea9d43892364","claim":"Cytek Biosciences, Inc. reported the year ended December 31, 2022 results: revenue $164.0 million, net income $2.5 million.","evidence_excerpt":"Total revenue for the year ended December 31, 2022 was $164.0 million, a 28% increase over the year ended December 31, 2021. On a constant currency basis, total revenue for the full year 2022 was $171.8 million, a 34% increase over the full year 2021. Gross profit was $101.0 million for the year ended December 31, 2022, an increase of 28% compared to a gross profit of $79.1 million in the year ended December 31, 2021. Gross profit margin was 62% in the year ended December 31, 2022 compared to 62% in the year ended December 31, 2021. Adjusted gross profit margin in the year ended December 31, 2022 was 63% compared to 63% in the year ended December 31, 2021, after adjusting for stock-based compensation expense and amortization of acquisition-related intangibles. Operating expenses were $102.8 million for the year ended December 31, 2022, a 47% increase from $70.0 million in the year ended December 31, 2021. The increase was primarily due to expenses to support continued growth of the bus","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831915/000119312523053897/0001193125-23-053897-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$164.0 million"},{"label":"Net income","value":"$2.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"cb1bc97379db185072b107d2b97a19456c037bae","claim":"Cytek Biosciences, Inc. reported the fourth quarter of 2022 results: revenue $48.3 million, net income $3.7 million.","evidence_excerpt":"Total revenue for the fourth quarter of 2022 was $48.3 million, a 24% increase over the fourth quarter of 2021, with continued demand across the full portfolio of Cytek’s offerings. On a constant currency basis, total revenue for the fourth quarter of 2022 was $51.2 million, a 32% increase over the fourth quarter of 2021. Gross profit was $29.4 million for the fourth quarter of 2022, an increase of 24% compared to a gross profit of $23.6 million in the fourth quarter of 2021. Gross profit margin was 61% in the fourth quarter of 2022 compared to 61% in the fourth quarter of 2021. Adjusted gross profit margin in the fourth quarter of 2022 was 62% compared to 63% in the fourth quarter of 2021, after adjusting for stock-based compensation expense and amortization of acquisition-related intangibles. Operating expenses were $29.3 million for the fourth quarter of 2022, a 31% increase from $22.3 million in the fourth quarter of 2021. The increase was primarily due to expenses to support conti","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831915/000119312523053897/0001193125-23-053897-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2022"},{"label":"Revenue","value":"$48.3 million"},{"label":"Net income","value":"$3.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}